Mint Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.20 M
as on 13-01-2025
- Paid Up Capital ₹ 3.08 M
as on 13-01-2025
- Company Age 17 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -16.61%
(FY 2021)
- Profit -69.20%
(FY 2021)
- Ebitda -60.16%
(FY 2021)
- Net Worth 1.34%
(FY 2021)
- Total Assets 17.87%
(FY 2021)
About Mint Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.20 M and a paid-up capital of Rs 3.08 M, as per Ministry of Corporate Affairs (MCA) records.
Chitra Sathappan, Sethuraman Sathappan, Muthu Umayal, and Two other members serve as directors at the Company.
- CIN/LLPIN
U51397TN2007PTC063756
- Company No.
063756
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jun 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Mint Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chitra Sathappan  | Director | 04-Jun-2007 | Current |
| Sethuraman Sathappan | Director | 04-Jun-2007 | Current |
| Muthu Umayal | Director | 04-Jun-2007 | Current |
| Kannan Umamaheshwari | Additional Director | 30-Jan-2024 | Current |
| Ramasamy Sivaprakasam | Director | 04-Jun-2007 | Current |
Financial Performance of Mint Pharmaceuticals.
Mint Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 16.61% decrease. The company also saw a substantial fall in profitability, with a 69.2% decrease in profit. The company's net worth moved up by a moderate rise of 1.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mint Pharmaceuticals?
In 2021, Mint Pharmaceuticals had a promoter holding of 82.00% and a public holding of 18.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Saidharshini Health Care Private LimitedActive 2 years 11 days
Kannan Umamaheshwari is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mint Pharmaceuticals?
Mint Pharmaceuticals has a workforce of 26 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mint Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mint Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
